Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Herein, we measured CYP2E1 activity and the expression of CD163 (an M2 marker) and CD68 (a pan-macrophage marker) in hepatofibrotic tissue from HCC patients (n = 26) with comparison to normal liver tissue (n = 26). 31116889 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE We finally obtained a list of only five genes (AGXT; ALDOB; CYP2E1; IGFBP3; TOP2A) that were differentially expressed in tumor and nontumor tissues across studies and were significantly correlated to HCC prognosis.Only AGXT had not been reported in HCC. 31771612 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Importantly, however, hepatofibrotic rats with higher CYP2E1 activity developed a more severe form of HCC. 29917271 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE Therefore, higher CYP2E1 activity might be a risk factor for HCC induced by DEN. 29467309 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Acetaldehyde dehydrogenase 2 (<i>ALDH2</i>) and cytochrome P450 2E1 (<i>CYP2E1</i>) have been associated with hepatocellular carcinoma (HCC) susceptibility and prognosis. 29765251 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE CYP2E1 may be an attractive target for enhanced antitumor effects of VK2 in hepatocellular carcinoma treatment. 28339022 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Herein, CYP2E1 activity and content were determined in fibrotic liver tissue from patients with hepatocellular carcinoma. 29348818 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Under abnormal conditions the excessive reactive oxygen species generation results in genetic predisposition of various genes (as ADH, ALDH, CYP2E1, GSTT1, GSTP1 and GSTM1) involved in xenobiotic metabolic pathways, associated with susceptibility to different liver related diseases such as fibrosis, cirrhosis and hepatocellular carcinoma. 26163595 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE CYP2E1 Pst I/Rsa I polymorphism may contribute to the proportion cases of HCC, which needs further investigations. 25185993 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Recently, down-expression of CYP2E1 was found in hepatocellular carcinoma (HCC) with the majority to be chronic hepatitis B virus (HBV) carriers. 25238230 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE Compared to controls, Cyp2E1 rsaI variant c2 genotype increased the risk of HBV related liver disease severity by 2.68 fold, the highest for HCC cases (3.981 folds, p=0.106); and was associated with higher histology activity index (HAI) (p<0.001) in CHBV patients. 23454624 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE The meta-analysis indicated that CYP2E1 Pst I/Rsa polymorphism was not associated with HCC risk, while the interaction between Pst I/Rsa polymorphism and alcohol consumption increased the risk of HCC. 22249978 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Our data showed that TSA selectively induced CYP2E1 in four studied human hepatocellular carcinoma (HCC) cell lines (Huh7, PLC/PRF/5, Hep3B and HepG2), but not in normal primary human hepatocytes. 20404016 2010
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking. 19643819 2009
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE HCC cell line HepG2 was infected with Ad-CYP2E1 to enhance the expression of CYP2E1, followed by treatment with low toxic dose of recombinant human Fas ligand (FasL, 0.5 ng/ml) in the presence of Actinomycin D (Act D, 125 ng/ml). 18497573 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Among the 27 CYPs, levels of 7 (CYP2B6, CYP-IIC, CYP2C9, CYP2C19, CYP3A5, CYP4F3 and CYP27A1) were significantly lower and levels of 2 (CYP2E1 and CYP4F2) were slightly lower in HCC with venous invasion than in HCC without venous invasion. 16077914 2005
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease LHGDN The aim of this study was to determine whether hepatitis C virus core protein and alcohol-inducible cytochrome P450 2E1 contribute to reactive oxygen species production and cytotoxicity in human hepatoma cells. 15633127 2005
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease LHGDN In the progression of cirrhosis and HCC, the expression level of CYP2E1 was gradually decreased and hardly detected until the late stage of HCC. 15162526 2004
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE In the progression of cirrhosis and HCC, the expression level of CYP2E1 was gradually decreased and hardly detected until the late stage of HCC. 15162526 2004
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Human hepatoma HepG2 cells with transduced CYP2E1 (E47 cells) were used as a model to generate ROS through CYP2E1-mediated ethanol metabolism. 15449375 2004
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease CTD_human In the progression of cirrhosis and HCC, the expression level of CYP2E1 was gradually decreased and hardly detected until the late stage of HCC. 15162526 2004
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE This review describes some of the biochemical and toxicological properties of CYP2E1, especially as it relates to alcohol metabolism and toxicity and the establishment of human hepatoma HepG2 cell lines that overexpress human CYP2E1. 14744237 2004
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 GeneticVariation disease BEFREE The high-activity CYP2E1 c2 allele was underrepresented among HCC patients with respect to other HCV categories, including cirrhosis. 12569554 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease LHGDN We examined changes in heme metabolism by analyzing gene expression of the non-specific delta-aminolevulinate synthase (ALAS-N), and heme oxygenase-1 (HO-1), the rate limiting enzyme in heme synthesis and catabolism, respectively, in the human hepatoma cell line HLE/2E1, in which CYP2E1 was overexpressed by transfection of its expression vector. 12469218 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE The effect of genetic polymorphisms for glutathione S-transferase ( GST) M1, GSTT1, GSTP1-1( GSTP1), cytochrome P450 2E1 ( CYP2E1) and aldehyde dehydrogenase 2 ( ALDH2) on the risk of hepatocellular carcinoma (HCC) was observed in 78 Japanese patients with HCC and 138 non-cancer hospital controls. 12759747 2003